Trellis Vitality Review (2026): $150 Semaglutide

Most telehealth sellers publish one semaglutide number and let you find out the rest at checkout. Trellis Vitality (trellisvitality.com) publishes a table: $150 a month at one month, $140 at three, $133 at six, with every dosage the same price.¹ The one-month column is labelled as such, so the cheapest rung is not being passed off as the standing rate, and the price does not climb as you titrate.

We checked it in August 2026. On its GLP-1 line it is the best-formed price disclosure in a batch of seven sellers we screened together. On everything else it is one of the vaguest, and the gap between those two halves is the story.

The semaglutide table

$150 a month if you pay monthly. $140 a month on a three-month plan, $133 on six. Tirzepatide runs $199, $189 and $179 on the same three rungs.¹ The page's own caption reads "per-month price; longer plans cost less per month", and a separate line states that all dosages are available at the same price.

Two things are worth pulling out of that. First, the month-to-month column exists at all — several sellers in this market publish only a prepay rate and print it with a "/mo" suffix, which is a different product wearing the same label. Second, dose-flat pricing is worth more than the headline. If your maintenance dose ends up at 1.7 or 2.4 mg, a provider that charges by dose will quietly cost you far more than one that does not; the ladder is laid out in our semaglutide dosage chart, and it is the reason a $150 flat rate beats a lot of cheaper-looking opening offers.

At $150 month-to-month, Trellis sits low on our price-ordered semaglutide board without relying on a prepay commitment to get there.

And then the rest of the catalogue

Four other programs are sold: NAD+, glutathione, lipo-MIC with B12, and tesamorelin. Each publishes exactly one figure, prefixed "treatment plans starting at" — $129, $93, $130 and $299 a month respectively.¹ There is no table behind any of them. We pulled the site's build scripts, the rendered page HTML and the intake payload looking for a rung structure, and there is none anywhere.

So we do not publish those four as monthly prices, and neither should you treat them as such. Given that the GLP-1 table's six-month rung sits about 12% under its one-month rung, the most likely reading is that $129, $93, $130 and $299 are the longest-prepay rungs and the month-to-month price is higher. That is an inference. We have not observed it, and we are not going to file a number we inferred.

There is a second, sharper problem here. Trellis's own blog states — twice, on a page about NAD+ cost — that Trellis publishes its complete pricing on the program page. It does not. The program pages publish a single "starting at" figure. A company being wrong about its own disclosure practices is a small thing on its own and a useful signal when you are deciding how much of the rest to take on trust.

What it does disclose properly

The pharmacy is named: VialsRX, a state-licensed compounding pharmacy in Houston, Texas. In this cohort that is the exception rather than the rule, and for a compounded product it is the single most useful thing a seller can tell you — the reasoning is in is compounded semaglutide still legal in 2026?.

Clinical work runs through Arora Health & Aesthetics, LLC, medical director Dr. Sean Arora, whose NPI (1841729449) resolves to an active Family Medicine record in the national registry.² Coverage is all 50 states. There is no membership fee and no consultation charge advertised, and the initial assessment is free — though the terms page is thin enough that we could not corroborate that in a legal document, and we could not find an LLC or Inc. filing name for the business anywhere on the site.

One thing to know if you are comparing: The Edit runs on the same medical group and the same medical director. Different pharmacy, different prices, genuinely separable products — but they are not independent clinical opinions on each other, and a shortlist containing both contains one prescribing organisation twice.

Numbers we are not going to repeat

The site carries a star rating, a current-patient count, an average-time-saved claim and an average-annual-savings figure. None of them is sourced anywhere on the site — no methodology, no review platform, no sample. We have not reproduced the figures here, and you should discount them entirely when comparing. The same caution applies to any provider's self-reported testimonials, which is why we treat what users actually report as a separate question from what a company claims about itself.

The regulatory screen

The trading name, the medical group and the named pharmacy all returned zero company-column matches in the FDA's live warning-letter index in August 2026, in a pass whose control query correctly returned a known February 2026 letter for an unrelated seller.³ Clean.

Where it lands

For a semaglutide buyer specifically, Trellis is one of the two or three strongest sellers in this batch: a published month-to-month rate, a published prepay structure, dose-flat pricing, a named pharmacy and a verifiable prescriber. $150 is a good number and it is a real one.

For anything else on its menu, you are buying on a "starting at" figure with nothing behind it, from a company whose own blog is wrong about how much it discloses. Treat the GLP-1 program and the rest of the catalogue as two different levels of evidence, because that is what they are. Then weigh it against Pepti's unresolved $99 and the rest of the programs we track.